News | August 30, 2025
MHRA approves UK’s first new type of antibiotic for urinary tract infections
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
The sale/transfer of the Company's API NonAntibiotic Business and API Antibiotic Business to Apitoria are complete
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
This order is subject to initial advance payment as per the agreed terms of the contract and this order will be executed within 6 to 8 months.
Zidavi is recommended by the Infectious Disease Society of America
Subscribe To Our Newsletter & Stay Updated
